Natera, Inc. (NASDAQ:NTRA) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
A number of other equities analysts also recently commented on the company. Zacks Investment Research downgraded Natera from a “buy” rating to a “sell” rating in a report on Saturday, August 12th. ValuEngine upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Morgan Stanley lowered their price target on Natera from $18.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, August 7th. Finally, Canaccord Genuity increased their price target on Natera from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, May 10th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $14.45.
Natera (NASDAQ:NTRA) opened at 11.64 on Wednesday. The stock’s market capitalization is $619.52 million. The firm has a 50-day moving average of $9.96 and a 200 day moving average of $9.64. Natera has a 12-month low of $7.35 and a 12-month high of $12.95.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52). Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The firm had revenue of $53.60 million for the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the prior year, the company posted ($0.46) earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. On average, analysts predict that Natera will post ($2.03) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Natera, Inc. (NTRA) Upgraded at BidaskClub” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://stocknewstimes.com/2017/08/23/natera-inc-ntra-upgraded-at-bidaskclub.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors boosted its position in shares of Natera by 7.3% in the first quarter. Nationwide Fund Advisors now owns 62,273 shares of the medical research company’s stock valued at $552,000 after buying an additional 4,246 shares during the period. Prudential Financial Inc. boosted its position in shares of Natera by 185.9% in the first quarter. Prudential Financial Inc. now owns 73,820 shares of the medical research company’s stock valued at $654,000 after buying an additional 48,000 shares during the period. Massachusetts Financial Services Co. MA raised its position in Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock valued at $143,000 after buying an additional 194 shares in the last quarter. Citadel Advisors LLC raised its position in Natera by 20.3% in the first quarter. Citadel Advisors LLC now owns 204,371 shares of the medical research company’s stock valued at $1,813,000 after buying an additional 34,510 shares in the last quarter. Finally, Foresite Capital Management II LLC bought a new position in Natera during the first quarter valued at about $450,000. 59.86% of the stock is owned by hedge funds and other institutional investors.
Natera Company Profile
Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
